The aim of this systematic review undertaken in 2013 and subsequent questionnaire was to investigate the consistency of methods for evaluation of ERCC1 as a biomarker predictive of response to platinum-based chemotherapy in ongoing or completed since 2007 studies in NSCLC, and to investigate the rationale for choice of a specific method. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.